Cimetidine disposition in obesity

D. R. Abernethy, D. J. Greenblatt, R. Matlis, R. Gugler

Research output: Contribution to journalArticle

Abstract

Cimetidine pharmacokinetics were studied in 13 otherwise healthy but obese volunteers, having a mean body weight of 113 kg and a mean percentage ideal body weight (IBW) of 179%. Sixteen healthy volunteers of normal body habitus (64 kg, 99% IBW) served as controls. All subjects had normal renal function and no laboratory or clinical evidence of hepatic or cardiac dysfunction. After administration of 200-300 mg of cimetidine by rapid intravenous injection, multiple plasma samples obtained over the next 24 h were analyzed for cimetidine concentration by high pressure liquid chromatography. Elimination half-life was not different between obese and control subjects (2.23 versus 2.08h). Apparent volume of distribution was also similar between subject groups (120 versus 106), as was total metabolic clearance (616 versus 579 ml/min). Using percentage IBW as a measure of obesity, no relationship was found between percentage IBW and apparent volume of distribution (r = 0.29). Cimetidine similarly distributes into IBW in both obese and normal weight subjects, and there is minimal distribution of cimetidine into excess body weight over IBW. Furthermore, there is no difference in total metabolic clearance or half-life of cimetidine between obese and control subjects. Cimetidine dosage in clinical practice should therefore be calculated on the basis of IBW, which beter reflects lean body mass, instead of total body weight, which reflects adipose tissue weight in addition to lean body mass.

Original languageEnglish (US)
Pages (from-to)91-94
Number of pages4
JournalAmerican Journal of Gastroenterology
Volume79
Issue number2
StatePublished - 1984
Externally publishedYes

Fingerprint

Ideal Body Weight
Cimetidine
Obesity
Body Weight
Half-Life
Healthy Volunteers
Weights and Measures
Intravenous Injections
Adipose Tissue
Pharmacokinetics
High Pressure Liquid Chromatography
Kidney
Liver

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Abernethy, D. R., Greenblatt, D. J., Matlis, R., & Gugler, R. (1984). Cimetidine disposition in obesity. American Journal of Gastroenterology, 79(2), 91-94.

Cimetidine disposition in obesity. / Abernethy, D. R.; Greenblatt, D. J.; Matlis, R.; Gugler, R.

In: American Journal of Gastroenterology, Vol. 79, No. 2, 1984, p. 91-94.

Research output: Contribution to journalArticle

Abernethy, DR, Greenblatt, DJ, Matlis, R & Gugler, R 1984, 'Cimetidine disposition in obesity', American Journal of Gastroenterology, vol. 79, no. 2, pp. 91-94.
Abernethy DR, Greenblatt DJ, Matlis R, Gugler R. Cimetidine disposition in obesity. American Journal of Gastroenterology. 1984;79(2):91-94.
Abernethy, D. R. ; Greenblatt, D. J. ; Matlis, R. ; Gugler, R. / Cimetidine disposition in obesity. In: American Journal of Gastroenterology. 1984 ; Vol. 79, No. 2. pp. 91-94.
@article{2fa8049c66d84e4ca8996febfe18eb0c,
title = "Cimetidine disposition in obesity",
abstract = "Cimetidine pharmacokinetics were studied in 13 otherwise healthy but obese volunteers, having a mean body weight of 113 kg and a mean percentage ideal body weight (IBW) of 179{\%}. Sixteen healthy volunteers of normal body habitus (64 kg, 99{\%} IBW) served as controls. All subjects had normal renal function and no laboratory or clinical evidence of hepatic or cardiac dysfunction. After administration of 200-300 mg of cimetidine by rapid intravenous injection, multiple plasma samples obtained over the next 24 h were analyzed for cimetidine concentration by high pressure liquid chromatography. Elimination half-life was not different between obese and control subjects (2.23 versus 2.08h). Apparent volume of distribution was also similar between subject groups (120 versus 106), as was total metabolic clearance (616 versus 579 ml/min). Using percentage IBW as a measure of obesity, no relationship was found between percentage IBW and apparent volume of distribution (r = 0.29). Cimetidine similarly distributes into IBW in both obese and normal weight subjects, and there is minimal distribution of cimetidine into excess body weight over IBW. Furthermore, there is no difference in total metabolic clearance or half-life of cimetidine between obese and control subjects. Cimetidine dosage in clinical practice should therefore be calculated on the basis of IBW, which beter reflects lean body mass, instead of total body weight, which reflects adipose tissue weight in addition to lean body mass.",
author = "Abernethy, {D. R.} and Greenblatt, {D. J.} and R. Matlis and R. Gugler",
year = "1984",
language = "English (US)",
volume = "79",
pages = "91--94",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Cimetidine disposition in obesity

AU - Abernethy, D. R.

AU - Greenblatt, D. J.

AU - Matlis, R.

AU - Gugler, R.

PY - 1984

Y1 - 1984

N2 - Cimetidine pharmacokinetics were studied in 13 otherwise healthy but obese volunteers, having a mean body weight of 113 kg and a mean percentage ideal body weight (IBW) of 179%. Sixteen healthy volunteers of normal body habitus (64 kg, 99% IBW) served as controls. All subjects had normal renal function and no laboratory or clinical evidence of hepatic or cardiac dysfunction. After administration of 200-300 mg of cimetidine by rapid intravenous injection, multiple plasma samples obtained over the next 24 h were analyzed for cimetidine concentration by high pressure liquid chromatography. Elimination half-life was not different between obese and control subjects (2.23 versus 2.08h). Apparent volume of distribution was also similar between subject groups (120 versus 106), as was total metabolic clearance (616 versus 579 ml/min). Using percentage IBW as a measure of obesity, no relationship was found between percentage IBW and apparent volume of distribution (r = 0.29). Cimetidine similarly distributes into IBW in both obese and normal weight subjects, and there is minimal distribution of cimetidine into excess body weight over IBW. Furthermore, there is no difference in total metabolic clearance or half-life of cimetidine between obese and control subjects. Cimetidine dosage in clinical practice should therefore be calculated on the basis of IBW, which beter reflects lean body mass, instead of total body weight, which reflects adipose tissue weight in addition to lean body mass.

AB - Cimetidine pharmacokinetics were studied in 13 otherwise healthy but obese volunteers, having a mean body weight of 113 kg and a mean percentage ideal body weight (IBW) of 179%. Sixteen healthy volunteers of normal body habitus (64 kg, 99% IBW) served as controls. All subjects had normal renal function and no laboratory or clinical evidence of hepatic or cardiac dysfunction. After administration of 200-300 mg of cimetidine by rapid intravenous injection, multiple plasma samples obtained over the next 24 h were analyzed for cimetidine concentration by high pressure liquid chromatography. Elimination half-life was not different between obese and control subjects (2.23 versus 2.08h). Apparent volume of distribution was also similar between subject groups (120 versus 106), as was total metabolic clearance (616 versus 579 ml/min). Using percentage IBW as a measure of obesity, no relationship was found between percentage IBW and apparent volume of distribution (r = 0.29). Cimetidine similarly distributes into IBW in both obese and normal weight subjects, and there is minimal distribution of cimetidine into excess body weight over IBW. Furthermore, there is no difference in total metabolic clearance or half-life of cimetidine between obese and control subjects. Cimetidine dosage in clinical practice should therefore be calculated on the basis of IBW, which beter reflects lean body mass, instead of total body weight, which reflects adipose tissue weight in addition to lean body mass.

UR - http://www.scopus.com/inward/record.url?scp=0021354380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021354380&partnerID=8YFLogxK

M3 - Article

C2 - 6364798

AN - SCOPUS:0021354380

VL - 79

SP - 91

EP - 94

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 2

ER -